Quantcast
Last updated on April 16, 2014 at 6:17 EDT

Latest MorphoSys Stories

2013-10-31 04:21:26

LONDON and BOSTON, October 31, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that members of its senior management team will be presenting at the following biotech industry events over the coming weeks. BIO-Europe 2013 [http://www.ebdgroup.com/bioeurope/index.php ] (Vienna, Austria, 4-6 November) Barry Kenny, Heptares' Chief Business Officer will present an overview of the Company at...

2013-10-10 04:21:07

WELWYN GARDEN CITY, England and BOSTON, Massachusetts, October 10, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, achieved the first research milestone in its antibody therapeutics alliance with MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX), announced in February 2013. The milestone is based on the generation of a stabilised (StaR(R)) form of the first GPCR target selected by MorphoSys, a key step...

2013-09-06 08:22:18

WELWYN GARDEN CITY, England and BOSTON, September 6, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, notes that it will be presenting at the following scientific conferences and biotech industry events over the coming weeks. 6th CNS Partnering and Deal-making conference [http://www.gtcbio.com/conference/cns-partnering-and-deal-making-overview ] (Boston, MA, USA, 9-10 September) Dan Grau, Heptares' President,...

2013-08-16 08:23:43

LONDON, August 16, 2013 /PRNewswire/ -- Edison Investment Research, a leading international investment research firm, announces the initiation of research coverage on the US-listed ADRs of MorphoSys (NASDAQ: MPSYY), a German biotech company developing human antibodies for therapeutic use. (Logo: http://photos.prnewswire.com/prnh/20130417/608168 ) The ADR initiation follows two landmark licensing deals struck with GlaxoSmithKline and Celgene that mark a...

2013-07-02 08:26:38

MONROVIA, Calif., July 2, 2013 /PRNewswire/ -- Xencor, Inc. announced today that that it has entered into a technology license and option agreement to provide Merck, known as MSD outside the United States and Canada, access to one of Xencor's Fc engineering patents for a therapeutic monoclonal antibody. Under the agreement, Merck will be granted a non-exclusive license to a Xencor patent for use in an undisclosed product, as well as an option to license the same intellectual property...

2013-06-07 08:24:26

DUBLIN, June 7, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/p98lsg/protein) has announced the addition of the "Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017" [http://www.researchandmarkets.com/research/p98lsg/protein ] report to their offering....

2013-06-06 04:21:03

WELWYN GARDEN CITY, England and BOSTON, June 6, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, notes that it will be presenting at the following biotech industry events over the coming weeks. EPIC European Partnering and Investment Conference [http://www.epicbiotech.com ] (London, UK, 6 June) Dr Barry Kenny, Heptares' Chief Business Officer, will present an overview of the Company at 4:00pm (BST). Boston Biotech CEO...

2013-05-24 04:20:31

WELWYN GARDEN CITY, England and BOSTON, May 24, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, is pleased to announce that it has engaged Mr Akira Usui as a Consultant to augment the Company's business development capabilities in Japan and other Asian territories. Mr Usui has more than 15 years of experience in business development, licensing and alliance management in the pharmaceutical industry including senior roles...

2013-04-29 04:21:17

WELWYN GARDEN CITY, England and BOSTON, April 29, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, announces it has achieved all milestones in its collaboration with Takeda Pharmaceutical Company. By achieving these milestones, Heptares will receive a significant payment from Takeda, under the terms of the agreement signed by the two companies in 2011. The agreement is focused on a single GPCR target nominated by Takeda...

2013-04-26 08:23:32

MONROVIA, Calif., April 26, 2013 /PRNewswire/ -- Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia (B-ALL). MOR208 is a potent anti-CD19 monoclonal antibody Fc optimized for high cytotoxic function for which MorphoSys licensed exclusive worldwide rights from Xencor in 2010. The dosing of the first patient in the study triggers an undisclosed milestone payment to Xencor. The US-based study is...